Abstract:Abstract Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality, underscores the urgent need for enhanced insights into the molecular and cellular mechanisms underlying metastasis, chemoresistance, and the mechanistic backgrounds of individuals whose cancers are prone to migration. The most prevalent signaling cascade governed by multi-kinase inhibitors is the mitogen-activated protein kinase (MAPK) pathway, encompassing the RAS–RAF–MAPK kinase (MEK)–extracellular signal-related kinase (ERK) pathway. RAF kinase is a primary mediator of the MAPK pathway, responsible for the sequential activation of downstream targets, such as MEK and the transcription factor ERK, which control numerous cellular and physiological processes, including organism development, cell cycle control, cell proliferation and differentiation, cell survival, and death. Defects in this signaling cascade are associated with diseases such as cancer. RAF inhibitors (RAFi) combined with MEK blockers represent an FDA-approved therapeutic strategy for numerous RAF -mutant cancers, including melanoma, non-small cell lung carcinoma, and thyroid cancer. However, the development of therapy resistance by cancer cells remains an important barrier. Autophagy, an intracellular lysosome-dependent catabolic recycling process, plays a critical role in the development of RAFi resistance in cancer. Thus, targeting RAF and autophagy could be novel treatment strategies for RAF -mutant cancers. In this review, we delve deeper into the mechanistic insights surrounding RAF kinase signaling in tumorigenesis and RAFi-resistance. Furthermore, we explore and discuss the ongoing development of next-generation RAF inhibitors with enhanced therapeutic profiles. Additionally, this review sheds light on the functional interplay between RAF-targeted therapies and autophagy in cancer.

Targeting RAS–ERK signalling in cancer: promises and challenges

ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

Targeting the RAS upstream and downstream signaling pathway for cancer treatment

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

Targeting the RAF–MEK–ERK pathway in cancer therapy

The MEK/ERK Network as a Therapeutic Target in Human Cancer

Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

Targeting RAF dimers in RAS mutant tumors: From biology to clinic

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

Targeting the ERK signaling pathway in cancer therapy

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

The current state of the art and future trends in RAS-targeted cancer therapies

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

Emerging strategies to target RAS signaling in human cancer therapy

Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma

Novel RAF‐directed approaches to overcome current clinical limits and block the RAS/RAF node

Reporter cell lines to screen for inhibitors or regulators of the KRAS-RAF-MEK1/2-ERK1/2 pathway